Four‐ to seven‐year follow‐up of pharmacological postconditioning with mangafodipir as an adjunct to primary PCI in ST‐segment elevation myocardial infarction

Abstract

AbstractIntroductionAdverse left ventricular remodelling (AR) develops over time in approximately 30% of patients with a history of coronary artery disease. AR manifests as a structural change in the left ventricle (LV) in terms of increased volumes and reduced left ventricular ejection fraction (LVEF). Manganese dipyridoxyl diphosphate (mangafodipir) has demonstrated interesting cardioprotective features in acute myocardial ischaemia. Pharmacological postconditioning (PP) with mangafodipir as an adjunct to primary percutaneous coronary intervention may possibly reduce the development of AR over time in ST‐elevation myocardial infarction (STEMI). The aim of this 4–7‐year follow‐up study is to investigate the potential benefits of PP with mangafodipir in STEMI patients.MethodThirteen out of the initial 20 patients that were included in the primary study of Karlsson et al. were followed up between April and June 2017. The study group underwent review of the hospital records, a clinical examination with ECG and blood sample analysis before cardiac magnetic resonance examination of the patient. LVEF, left ventricular diastolic volume, left ventricular end systolic volume, LV mass and myocardial strain in all directions were computed.ResultsThe PP group showed a decrease in LV volume, mass and higher LVEF at follow‐up (p < 0.05) while the individual response of the placebo group showed features that are seen in AR. Although there was no difference in myocardial strain, measurement for the PP‐group was higher in absolute terms.ConclusionPharmacological postconditioning with mangafodipir in STEMI demonstrated cardioprotective features compared to the placebo group at follow‐up. This article is protected by copyright. All rights reserved.